$CRNX
Crinetics Pharmaceuticals, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019007561 Filed on March 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $367.0K $781.0K $2.428M
YoY Change -16.97% 47.92% 18.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.160M $2.560M $6.660M
YoY Change 152.8% 444.68% 243.3%
% of Gross Profit
Research & Development $7.255M $7.651M $24.48M
YoY Change 53.71% 198.63% 165.13%
% of Gross Profit
Depreciation & Amortization $200.0K $210.0K $500.0K
YoY Change 300.0% 320.0% 284.62%
% of Gross Profit
Operating Expenses $10.41M $10.21M $31.14M
YoY Change 74.45% 237.14% 178.71%
Operating Profit -$10.04M -$28.71M
YoY Change 81.76% 214.56%
Interest Expense $1.010M $1.000M $1.750M
YoY Change 1583.33% 9900.0% 21775.0%
% of Operating Profit
Other Income/Expense, Net $1.028M -$60.00K $1.595M
YoY Change 1558.06% 100.0% -5416.67%
Pretax Income -$9.020M -$8.500M -$27.12M
YoY Change 65.2% 237.3% 196.11%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.016M -$8.495M -$27.12M
YoY Change 65.01% 236.97% 196.11%
Net Earnings / Revenue -2456.68% -1087.71% -1116.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$374.3K -$344.8K -$1.121M
COMMON SHARES
Basic Shares Outstanding 24.10M 24.04M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.2M $163.9M $163.9M
YoY Change 113.3% 1054.23%
Cash & Equivalents $63.33M $44.97M $45.00M
Short-Term Investments $94.40M $118.9M $118.9M
Other Short-Term Assets $1.063M $876.0K $1.200M
YoY Change 254.33% 266.53% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $159.1M $166.7M $166.7M
YoY Change 113.01% 999.13% 996.71%
LONG-TERM ASSETS
Property, Plant & Equipment $4.465M $4.232M $4.200M
YoY Change 793.0% 958.0% 950.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $500.0K
YoY Change -37.5% 1415.15%
Total Long-Term Assets $7.648M $4.732M $4.700M
YoY Change 378.0% 992.84% 1075.0%
TOTAL ASSETS
Total Short-Term Assets $159.1M $166.7M $166.7M
Total Long-Term Assets $7.648M $4.732M $4.700M
Total Assets $166.8M $171.4M $171.4M
YoY Change 118.56% 998.95% 998.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.003M $1.456M $1.500M
YoY Change 54.08% 261.29% 275.0%
Accrued Expenses $5.304M $4.190M $6.500M
YoY Change 194.67% 2240.78% 1200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.818M $7.925M $7.900M
YoY Change 184.45% 783.5% 777.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.600M $3.300M $3.300M
YoY Change 2700.0%
Total Long-Term Liabilities $5.600M $3.300M $3.300M
YoY Change 2700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.818M $7.925M $7.900M
Total Long-Term Liabilities $5.600M $3.300M $3.300M
Total Liabilities $14.37M $11.19M $11.20M
YoY Change 335.42% 1116.3% 1144.44%
SHAREHOLDERS EQUITY
Retained Earnings -$52.40M -$43.38M
YoY Change 166.71%
Common Stock $203.5M
YoY Change 16275.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $152.4M $160.2M $160.2M
YoY Change
Total Liabilities & Shareholders Equity $166.8M $171.4M $171.4M
YoY Change 118.56% 998.95% 998.72%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$9.016M -$8.495M -$27.12M
YoY Change 65.01% 236.97% 196.11%
Depreciation, Depletion And Amortization $200.0K $210.0K $500.0K
YoY Change 300.0% 320.0% 284.62%
Cash From Operating Activities -$6.759M -$6.010M -$19.46M
YoY Change 98.39% 139.44% 105.29%
INVESTING ACTIVITIES
Capital Expenditures $408.0K -$280.0K $1.059M
YoY Change 615.79% 21.74% 248.36%
Acquisitions
YoY Change
Other Investing Activities $25.01M -$118.4M -$118.4M
YoY Change
Cash From Investing Activities $24.60M -$118.7M -$119.5M
YoY Change -43256.14% 51500.0% 39195.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $106.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 10.00K 170.2M
YoY Change -99.97% -99.86% 1339.55%
NET CHANGE
Cash From Operating Activities -6.759M -6.010M -19.46M
Cash From Investing Activities 24.60M -118.7M -119.5M
Cash From Financing Activities 20.00K 10.00K 170.2M
Net Change In Cash 17.86M -124.7M 31.28M
YoY Change -70.26% -2979.45% 1433.38%
FREE CASH FLOW
Cash From Operating Activities -$6.759M -$6.010M -$19.46M
Capital Expenditures $408.0K -$280.0K $1.059M
Free Cash Flow -$7.167M -$5.730M -$20.52M
YoY Change 106.9% 151.32% 109.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2279000
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44973000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14192000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
118902000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2808000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
973000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
166683000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15165000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4232000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
400000
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001658247
CY2018 dei Entity Registrant Name
EntityRegistrantName
Crinetics Pharmaceuticals, Inc.
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24095485
CY2018Q3 dei Entity Public Float
EntityPublicFloat
382100000
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-28710000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5100000
CY2018 dei Trading Symbol
TradingSymbol
CRNX
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
1748000
CY2017 crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
2000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-9157000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-6019000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.23
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.68
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12142000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1371000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1011000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2018Q4 us-gaap Assets
Assets
171415000
CY2017Q4 us-gaap Assets
Assets
15598000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1456000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
403000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
315000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4190000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
179000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7925000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
897000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3063000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
20000
CY2018Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
202000
CY2017Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
3000
CY2018Q4 us-gaap Liabilities
Liabilities
11190000
CY2017Q4 us-gaap Liabilities
Liabilities
920000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
29700000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
203520000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1242000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
61000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43380000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16265000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160225000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-15022000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171415000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15598000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50500000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24187568
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2076171
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24060510
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1549575
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2428000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2045000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
589000
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2016 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2017 us-gaap Interest Expense
InterestExpense
8000
CY2016 us-gaap Interest Expense
InterestExpense
11000
CY2018 us-gaap Other Expenses
OtherExpenses
153000
CY2017 us-gaap Other Expenses
OtherExpenses
48000
CY2016 us-gaap Other Expenses
OtherExpenses
1000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1595000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-27115000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27054000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9157000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6019000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.96
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-463000
CY2016 crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
8000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
270000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-6204000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
92975000
CY2018 crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
21000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
231000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2320000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
61000
CY2017 crnx Temporary Equity Stock Issuance Costs
TemporaryEquityStockIssuanceCosts
40000
CY2018 crnx Temporary Equity Stock Issuance Costs
TemporaryEquityStockIssuanceCosts
225000
CY2018 crnx Issuance Cost Of Common Stock In Initial Public Offering
IssuanceCostOfCommonStockInInitialPublicOffering
10829000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2320000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
271000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
270000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
471000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
128000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
92000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
433000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1802000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
783000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
116000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7361000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
47000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
300000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-261000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
15000
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
5000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19459000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9479000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5468000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
118399000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1059000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
304000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
190000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119458000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-304000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-190000
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
63275000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11969000
CY2016 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
-5000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
106472000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
451000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
CY2017 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
212000
CY2016 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
48000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170198000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11823000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-53000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31281000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2040000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5711000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14192000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12152000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17863000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45473000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
8000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2018 crnx Purchase Of Shares Pursuant To Employee Stock Purchase Plan
PurchaseOfSharesPursuantToEmployeeStockPurchasePlan
282000
CY2018 crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
21000
CY2017 crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
2000
CY2016 crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
8000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000
CY2018 crnx Tenant Improvement Allowance
TenantImprovementAllowance
3304000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
239000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4973000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
704000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
741000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
304000
CY2018Q4 crnx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3634000
CY2017Q4 crnx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
126000
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
381000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to revenue recognition, accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
175000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.37
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.94
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.91
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.40
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.54
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1058000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1123000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1173000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1208000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6355000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2127000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2664000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1863000
CY2018Q4 crnx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
12577000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1244000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2151000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7957000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
838276
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2002332
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
479287
CY2018 crnx Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired
22164
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2339157
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
250090
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.80
CY2018 us-gaap Tax Credit Carryforward Limitations On Use
TaxCreditCarryforwardLimitationsOnUse
Future utilization of the Company’s NOL and R&D credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that may have occurred or that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups.
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
163900000
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
118841000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
74000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
118902000
CY2018Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P24M
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
568000
CY2017Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
231000
CY2018Q4 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
1016000
CY2017Q4 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
503000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1224000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1788000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
829000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2479000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
38000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
866000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
22000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
157000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
23000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1600000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
10900000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
100000
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2403000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55257000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6366000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.66
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.85
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2320000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
270000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7900000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
8700000
CY2017Q4 crnx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
4858000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12577000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4858000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25876000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8141000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6019000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1239000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1016000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27115000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9157000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6019000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5694000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3113000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2046000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1758000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-474000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
442000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-327000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7724000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2112000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2511000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1129000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
525000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
342000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-52000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1602000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2018 us-gaap Income Tax Reconciliation Tax Settlements Foreign
IncomeTaxReconciliationTaxSettlementsForeign
362000
CY2017 us-gaap Income Tax Reconciliation Tax Settlements Foreign
IncomeTaxReconciliationTaxSettlementsForeign
176000
CY2016 us-gaap Income Tax Reconciliation Tax Settlements Foreign
IncomeTaxReconciliationTaxSettlementsForeign
0
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
547000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
222000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
204000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
159000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
68000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
185000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
91000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
68000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
344000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2466000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10108000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6916000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
657000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
548000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781000
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4720000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5222000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6886000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7651000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1248000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1118000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1732000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2561000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5968000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
6340000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
8618000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
10212000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5464000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5568000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7588000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-8495000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.92
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.41
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
832000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
640000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
528000
CY2017Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2065000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2083000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2523000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2562000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
589000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
392000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
491000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
467000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
2654000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
2475000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
3014000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
3029000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2606000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1648000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2382000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2521000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68

Files In Submission

Name View Source Status
0001564590-19-007561-index-headers.html Edgar Link pending
0001564590-19-007561-index.html Edgar Link pending
0001564590-19-007561.txt Edgar Link pending
0001564590-19-007561-xbrl.zip Edgar Link pending
crnx-10k_20181231.htm Edgar Link pending
crnx-20181231.xml Edgar Link completed
crnx-20181231.xsd Edgar Link pending
crnx-20181231_cal.xml Edgar Link unprocessable
crnx-20181231_def.xml Edgar Link unprocessable
crnx-20181231_lab.xml Edgar Link unprocessable
crnx-20181231_pre.xml Edgar Link unprocessable
crnx-ex231_815.htm Edgar Link pending
crnx-ex311_10.htm Edgar Link pending
crnx-ex312_8.htm Edgar Link pending
crnx-ex321_11.htm Edgar Link pending
crnx-ex322_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
guw4jaqnypib000001.jpg Edgar Link pending
guw4jaqnypib000002.jpg Edgar Link pending
guw4jaqnypib000003.jpg Edgar Link pending
guw4jaqnypib000004.jpg Edgar Link pending
guw4jaqnypib000005.jpg Edgar Link pending
guw4jaqnypib000006.jpg Edgar Link pending
guw4jaqnypib000007.jpg Edgar Link pending
guw4jaqnypib000008.jpg Edgar Link pending
guw4jaqnypib000009.jpg Edgar Link pending
guw4jaqnypib000010.jpg Edgar Link pending
guw4jaqnypib000011.jpg Edgar Link pending
guw4jaqnypib000012.jpg Edgar Link pending
guw4jaqnypib000013.jpg Edgar Link pending
guw4jaqnypib000014.jpg Edgar Link pending
guw4jaqnypib000015.jpg Edgar Link pending
guw4jaqnypib000016.jpg Edgar Link pending
guw4jaqnypib000017.jpg Edgar Link pending
guw4jaqnypib000018.jpg Edgar Link pending
guw4jaqnypib000019.jpg Edgar Link pending
guw4jaqnypib000020.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending